Status:
COMPLETED
Radiosensitizing and Radioprotectve Effects of Curcumin in Prostate Cancer
Lead Sponsor:
Shahid Beheshti University of Medical Sciences
Conditions:
Prostate Cancer
Radiation Therapy
Eligibility:
MALE
50-80 years
Phase:
NA
Brief Summary
Prostate cancer is the second most incident cancer among male population worldwide. Radiation therapy by itself or along with surgery and chemotherapy are the main treatments for prostate cancer howev...
Eligibility Criteria
Inclusion
- Histologically confirmed adenocarcinoma of the prostate
- Age range of 50-80
- ECOG performance status 0-1
- Life expectancy \> 5 years
- Must be enrolled in a social security program
- No other cancer, except basal cell skin cancer, that has been treated or relapsed within the past 5 years
- No severe uncontrolled hypertension (systolic BP ≥ 160 mm Hg or diastolic BP ≥ 90 mm Hg)
- No contraindication to luteinizing hormone-releasing hormone agonists
- No contraindication to pelvic irradiation (e.g., scleroderma, chronic inflammatory gastrointestinal disease)
- No hip prosthesis
- Must not be deprived of liberty or under guardianship
- No geographical, social, or psychological reasons that would preclude follow up
Exclusion
- Clinical stage T3 or T4
- Gleason score ≥ 8
- Serum PSA ≥ 20 ng/mL and ≤ 100 ng/mL
- other prior surgery for prostate cancer
- concurrent participation in another clinical trial which would require approval upon entry to this trial
- Gastrointestinal disorders such as IBD, reflux and peptic ulcers
- Any adverse reaction to curcumin
Key Trial Info
Start Date :
March 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01917890
Start Date
March 1 2011
End Date
October 1 2013
Last Update
November 18 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oncology and radiotherapy department, Besat Hospital
Tehran, Tehran Province, Iran, 556432412